MedicineCostHelp
COVERAGE ENGINE · PRODUCT + DIAGNOSIS + INSURANCE

How do I get Lytenava
through my insurance?

Lytenava · bevacizumab-vikg · FDA-approved ophthalmic bevacizumab

Coverage first → benefit/formulation → assistance
Lytenava coverage navigator.

FDA approved July 2026 for neovascular (wet) age-related macular degeneration. Coverage, product preference, U.S. commercial availability and coding are still developing.

New-product note: FDA approved July 24, 2026; Outlook Therapeutics has announced a planned U.S. commercial launch before the end of 2026. Verify current availability and coding.

No account, member ID, name, date of birth or email is needed. Your selections stay in this page session.

1
WHY IS THIS MEDICINE BEING GIVEN?

Choose the diagnosis / reason.

Coverage rules can change by diagnosis and sometimes by formulation.

AFTER COVERAGE

Then solve the patient’s out-of-pocket cost.

Financial assistance only helps after the correct product/formulation and benefit path are known.

Outlook Therapeutics — LYTENAVA information →

Important

MedicineCostHelp is an educational navigation tool, not an insurer and not a coverage determination. Medical policies, billing codes, product preferences, availability and benefit placement can change. Sources were checked 2026-08-21.

Build a next-step action plan →